Idiopathic intracranial hypertension
Thaller, Mark; Mytton, Jemma; Wakerley, Benjamin; Mollan, Susan; Sinclair, Alex

DOI: 10.1111/1471-0528.17241
License: Creative Commons: Attribution (CC BY)

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):
Thaller, M, Mytton, J, Wakerley, B, Mollan, S & Sinclair, A 2022, 'Idiopathic intracranial hypertension: Evaluation of births and fertility through the Hospital Episode Statistics dataset', BJOG: An International Journal of Obstetrics & Gynaecology, vol. 129, no. 12, pp. 1-9. https://doi.org/10.1111/1471-0528.17241

Link to publication on Research at Birmingham portal

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• Users may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.
RESEARCH ARTICLE

Idiopathic intracranial hypertension: Evaluation of births and fertility through the Hospital Episode Statistics dataset

Mark Thaller1,2 | Jemma Mytton3 | Benjamin R. Wakerley1,2 | Susan P. Mollan4 | Alexandra J. Sinclair1,2,5

Abstract

Objective: Idiopathic intracranial hypertension (IIH) predominantly affects women of reproductive age with obesity, and these women have a distinct profile of hyperandrogenism and insulin resistance. Polycystic ovary syndrome (PCOS) has an established adverse fertility phenotype that typically affects obese women. As IIH may impact reproductive health, we sought to evaluate fertility, gestational complications and pregnancy outcome in IIH.

Design: Prospective cohort study from English Hospital Episode Statistics dataset.

Setting: English hospitals, UK.

Population: Women aged 18–45 years seen in English hospitals between 1 April 2002 and 31 March 2019. Patients were required to have an IIH diagnosis and were compared with those with PCOS and general population female controls.

Main outcome measures: Pregnancies resulting in live births, complications of gestational diabetes and pre-eclampsia, and method of delivery.

Results: Data was collected from 17 587 IIH, 199 633 PCOS and 10 947 012 women in the general population. The live birth rate, adjusted for age, was significantly lower among women with IIH (54.1%) than PCOS (67.9%), p < 0.0001 and the general population (57.7%), p < 0.0001. Pre-eclampsia and gestational diabetes risks were higher following a diagnosis of IIH (5.3-fold and 2.7-fold, respectively, p < 0.0001) compared with the general population controls. Following a diagnosis of IIH, elective caesarean section rates were more than twice that of general population (odds ratio [OR] 2.4) and prior to a diagnosis of IIH (OR 2.2).

Conclusions: These data indicate there are lower age-adjusted total pregnancy rates, increased risk of pre-eclampsia and gestational diabetes, and a doubling of elective caesarean section rates in those with a diagnosis of IIH.

KEYWORDS
birth, caesarean section, epidemiology, fertility, Hospital Episode Statistics, idiopathic intracranial hypertension, papilloedema, polycystic ovarian syndrome, pregnancy, pseudotumor cerebri
1 | INTRODUCTION

Idiopathic intracranial hypertension (IIH) is a disorder of raised intracranial pressure typically manifesting in reproductive-aged women with obesity. The incidence in women has increased by over 350% in the last decade to 9.3 per 100,000.1–4 Typical manifestations of the disease are debilitating headaches and visual loss,5,6 with many having cognitive dysfunction7 and obstructive sleep apnoea.8 More recently, evidence has pointed towards a condition of metabolic dysregulation.9 IIH patients have preferentially distributed truncal adiposity10 as well as increased risk of cardiovascular disease9 and insulin resistance in excess of that driven by obesity.11 IIH adipocyte function demonstrates a distinct transcriptional profile with adipocytes programmed for lipogenesis and weight gain.11

IIH patients have a unique hormone signature characterised by androgen excess with increased serum testosterone, and increased CSF testosterone and androstenedione, which has been found to be distinct from that observed in polycystic ovarian syndrome (PCOS) and simple obesity.12 IIH is phenotypically similar to PCOS, with both conditions typically occurring in women of reproductive age with obesity. A community-based PCOS study found a self-reported association of a 15-fold increase in infertility.13 The impact of IIH on reproductive health is not known and is an area declared as a high priority by patients.14 We hypothesised that fertility may be reduced in IIH, there may be an increase in the metabolic complications of gestational diabetes and pre-eclampsia, and that there may be an increased surgical delivery rate. The aims of this study were to evaluate the impact of a diagnosis of IIH on women’s fertility rates, pregnancy complications (gestational diabetes mellitus and pre-eclampsia) and method of delivery using the English National Health Service (NHS) Hospital Episode Statistics (HES) dataset.

2 | METHODS

2.1 | Study design

Data were obtained from the English National Health Service (NHS) Hospital Episode Statistics (HES) dataset, a registered administrative dataset. All women aged between 18 and 45 years, admitted to all hospitals (both private and public) in England between 1 April 2002 and 31 March 2019 were selected. Clinical episodes are defined as admissions to ambulatory care (e.g. for lumbar punctures), emergency room visits and inpatient care. Each clinical episode taking place in National Health Service (NHS) hospitals or NHS commissioned activity in the independent sector was recorded. Each record was anonymised and comprised specific demographic details of the admitted patient including age group, gender, ethnicity and geographical information such as the location of treatment and domicile. Coding was either ICD-10 (International Classification of Diseases, 10th revision)15 or OPCS-4 (Office of Population, Censuses and Surveys Classification of Interventions and Procedures, 4th revision) codes.16 Body mass index (BMI) is not recorded within HES data.

University Hospitals Birmingham NHS Foundation Trust possesses a Data Re-Use Agreement for the interrogation of the HES. The research involved non-identifiable information, previously collected during patient care and available for public use. Where there are <5 people in any category, the results were not made available to ensure anonymisation was upheld. University Hospitals Birmingham National Health Service Foundation Trust approved this study (Registered Code, Clinical Audit Registration and Management System: CARMS-17157).

A diagnosis of IIH in the UK is made by the hospital specialist. Typically, they should follow the consensus guidelines for this diagnosis, which include the presence of papilloedema; normal neurological examination except for cranial nerve abnormalities; normal neuroimaging (except for the accepted signs of raised intracranial pressure) including venography; a raised lumbar puncture opening pressure (≥25 cm cerebrospinal fluid [CSF] in adults); and with normal CSF constituents.6 This diagnosis is coded by the administrative staff and transmitted to the HES data set on a yearly basis. While the inclusion criteria for diagnosis are detailed to 31 March 2019, pregnancy outcome data was extracted up to 31 March 2020 so that all participants had at least a 1-year follow-up.

Three further groups were extracted for comparison purposes with the same age range and time frame: women diagnosed with PCOS and no IIH (PCOS), women with both IIH and PCOS diagnoses (IIH & PCOS) and women admitted for any other reason without IIH and without PCOS (general population) (Figure 1). Exclusion criteria were applied to help refine the data and ensure against miscoding of secondary causes of raised intracranial pressure such as brain tumours, hydrocephalus and cerebral venous sinus thrombosis. Due to the very high number of admitted patient care episodes and comorbidities, we excluded those with a history of dialysis, as these were likely to represent a secondary cause of raised intracranial pressure and the high admission rates would have potentially biased the results. Those who resided outside of England or whose residence was unknown were also excluded, as accurate longitudinal patient tracking was not always possible. Date of diagnosis for IIH (first coded) was used to enable comparison of data before (pre-IIH) and after IIH diagnosis (post-IIH). Patients were not directly involved in this study.

Tweetable abstract: Increased risks of pre-eclampsia, gestational diabetes and doubling of planned c-section with lower fertility seen in #IIH.
2.2 | Data collection

All coded pregnancies, births and losses (miscarriages and stillbirths) were collected. Table S1 lists the ICD-10 or OPCS-4 codes included and excluded from this study. The data were analysed by age at pregnancy and number of pregnancies/births/losses per female. Fertility was evaluated using a surrogate measure of the number of women without any pregnancies during this study period, as well as the total fertility rate, which is age-adjusted and based on the age-specific fertility rate.

Gestational complications of gestational diabetes (GDM) and pre-eclampsia were compared, with gestational hypertension without proteinuria (ICD10 O13) alone excluded from the latter. Delivery method (normal live delivery, assisted live delivery, emergency or elective caesarean section [CS]) and number of births were also retrieved. The data were divided by the occurrences pre- or post-IIH diagnosis for both the IIH and IIH & PCOS groups. The codes used for inclusion, exclusion and outcomes are listed in Table S1.

2.3 | Statistical analysis

The data were initially explored through descriptive analysis of variables using t-tests for quantitative variables and McNemar’s binomial tests for categorical variables to compare different groups. Poisson regression analysis was used to model the total number of pregnancies per patient with adjustments for age at first pregnancy and timing of IIH diagnosis in relation to their first pregnancy. Patients were included in this analysis if they had at least one pregnancy. Odds ratios (OR) were calculated using the Woolf logit method through logistic regression to enable comparison in complication and method of delivery outcomes between the IIH, PCOS and general population groups.

All statistical analyses were conducted using GraphPad Prism™ (version 9.1.0) with level of statistical significance set at p < 0.5.

3 | RESULTS

3.1 | Demographics

Pregnancy data were analysed for 17 587 patients diagnosed with IIH, 199 633 with PCOS, 1942 IIH&PCOS, and 10 947 012 in the general population. In the general population, the incidence of IIH per 100 000 women was 3.1, PCOS was 44.8, and IIH with comorbid PCOS was 0.36 (2018–2019). Mean age at pregnancy was similar post-IIH diagnosis, regardless of whether it was pre- or post-IIH diagnosis (Table 1).

3.2 | Fertility and pregnancy

During the study, 19 680 pregnancies were reported in women who were diagnosed with IIH, compared with 277 067 in PCOS, 1942 IIH&PCOS, and 11 848 846 in the general population. In the general population, the incidence of IIH per 100 000 women was 3.1, PCOS was 44.8, and IIH with comorbid PCOS was 0.36 (2018–2019). Mean age at pregnancy was similar post-IIH diagnosis, compared with the general population.
general population (incidence rate ratio (IRR) 0.53 (0.52–0.54) (p < 0.001), indicating that this is not an age effect. The predicted total number of pregnancies in IIH was 0.95 (0.94–0.96) in contrast to 1.80 (1.80–1.80) for the general population. Following an IIH diagnosis, the number of pregnancies decreased by 41.5% from 12 419 to 7261 (Table 1). Following diagnosis of IIH in patients with comorbid PCOS, pregnancies decreased by 27.2% from 1262 to 918. Following a diagnosis of IIH, women were less likely to have a further pregnancy compared with prior to an IIH diagnosis: IRR 0.83 (0.80–0.86), p < 0.001. There were fewer women with ≥2 pregnancies post-IIH diagnosis (1775, 10.1%) than pre-IIH diagnosis (3553, 20.2%) (Figure 2B) despite a similar mean age pre- and post-IIH diagnosis (Table 1). Infertility, inferred by the absence of pregnancies, occurred in 60.3% of women pre-IIH diagnosis and increased to 72.6% (p < 0.0001) post-IIH diagnosis (Figure 2B, Table 1), in comparison with 40.8% in the general population.

3.3 | Timing of IIH diagnosis and pregnancy

We explored the timing of IIH diagnosis and pregnancy. Where there was a pre-IIH diagnosis pregnancy, the last pregnancy occurred more than 3 years previously in 62.5%. Where IIH was diagnosed during pregnancy, this was predominantly in the second and third trimester (1035 [5.9%] of IIH patients overall) with a reduced diagnostic proportion (219 [1.2%]) during the immediate 6 months postpartum.

3.4 | Complications

Gestational diabetes was higher in IIH (12.3%) and PCOS (11.8%) patients compared with the general population (5.0%) (Table 1). In women prior to a diagnosis of IIH, gestational diabetes was lower (4.4%). The risk of developing gestational diabetes was higher following an IIH diagnosis (OR 3.01 [2.61–3.48], p < 0.0001) and when compared with the general population (OR 2.67 [2.45–2.91], p < 0.0001) (Figure 3), but there was no difference compared with patients with PCOS (p = 0.2751).

Pre-eclampsia was higher in IIH patients (11.8%), compared with the general population (2.5%), PCOS patients (4.3%) and prior to a diagnosis of IIH (4.2%). The probability of developing pre-eclampsia in IIH was higher than in the general population (OR 5.26 [4.82–5.74], p < 0.0001), PCOS (OR 2.97 [2.71–3.25], p < 0.0001) or compared with those

---

**TABLE 1** Demographics, pregnancy complications and assisted delivery method. The complication and assisted delivery percentages are for those who had at least one pregnancy

|          | IIH | IIH & PCOS | General population |
|----------|-----|------------|--------------------|
|          | Pre-IIH | Post-IIH | PCOS | Pre-IIH | Post-IIH |          |
| Demographics | Females 18–45 years, n | 17 587 | 199 633 | 1942 | 10 947 012 |
| Pregnancies, n | 12 419 | 7261 | 277 067 | 1262 | 918 | 11 848 46 |
| Pregnancy losses, n (%) | 1017 (8.2%) | 548 (7.5%) | 35 177 (12.7%) | 160 (12.7%) | 98 (10.7%) | 962 828 (8.1%) |
| Females with zero pregnancies, n (%) | 10 607 (60.3%) | 12 774 (72.6%) | 59 860 (30.0%) | 1221 (62.9%) | 1319 (67.9%) | 4 464 198 (40.8%) |
| Age at pregnancy, mean (SD) | 25.0 (5.1) | 28.6 (5.0) | 29.0 (5.5) | 24.7 (4.8) | 29.4 (4.9) | 29.6 (5.8) |
| Complications | Gestational diabetes, n (%) | 310 (4.4%) | 591 (12.3%) | 16 444 (11.8%) | 59 (8.2%) | 128 (20.6%) | 322 596 (5.0%) |
| Pre-eclampsia, n (%) | 290 (4.2%) | 570 (11.8%) | 6055 (4.3%) | 41 (5.7%) | 59 (9.5%) | 161 546 (2.5%) |
| Assisted delivery | Assisted vaginal delivery, n (%) | 1067 (9.4%) | 528 (7.9%) | 29 405 (12.2%) | 122 (10.2%) | 57 (6.9%) | 1 302 447 (12.0%) |
| Elective caesarean section, n (%) | 1266 (11.1%) | 1500 (22.3%) | 30 275 (12.5%) | 125 (11.3%) | 224 (27.3%) | 1 171 464 (10.8%) |
| Emergency caesarean section, n (%) | 1900 (16.7%) | 1325 (19.7%) | 44 231 (18.3%) | 199 (18.1%) | 199 (24.2%) | 1 615 195 (14.8%) |

**FIGURE 2** (A) Age-specific fertility rate in IIH (pre- and post-diagnosis) and general population in 2015. (B) Impact on pregnancy numbers following an IIH diagnosis. (C) Impact on delivery method following an IIH diagnosis. ****McNemar p < 0.0001.
prior to a diagnosis of IIH (OR 3.10 [2.68–3.59], $p < 0.0001$) (Figure 3).

### 3.5 Delivery method

Rates of assisted vaginal delivery, elective and emergency caesarean section were evaluated (Figure 2C). We found that the occurrence of elective caesarean section doubled following IIH diagnosis (from 11.1% to 22.3%) (Figure 2C), with the probability being statistically significantly higher (OR 2.16, 95% confidence interval [CI] 1.99–2.35, $p < 0.0001$). Additionally, the probability of elective caesarean section was statistically significantly higher compared with the general population (OR 2.39, 95% CI 2.26–2.54, $p < 0.0001$) and PCOS groups (OR 2.01, 95% CI 1.90–2.14, $p < 0.0001$) (Figure 3). The highest probability of elective caesarean section was among those with both IIH and PCOS (OR 3.12, 95% CI 2.67–3.64, $p < 0.0001$). Emergency caesarean section was also consistently higher in patients with IIH (Figure 3).

### 4 DISCUSSION

#### 4.1 Main findings

This large observational study found that patients with IIH had statistically significantly fewer pregnancies, more pregnancy-related complications (gestational diabetes and pre-eclampsia) and were more likely to have caesarean sections. Although fertility normally decreases with increased age, this study indicates that age-specific fertility rates at the vast majority of time points were lower in IIH both pre- and post-diagnosis compared with the general population.
4.2 | Interpretation

This is the first study to report that people with IIH may have reduced fertility. The cause of this reduction is likely to be multifactorial. Obesity is known to affect fertility.\textsuperscript{10,18,19} It increases the risk of menstrual irregularities, typically as a result of anovulation.\textsuperscript{19} This is through decreased luteinizing hormone pulse amplitude,\textsuperscript{20} which can lead to abnormal oocyte recruitment and quality.\textsuperscript{21} Circulating adipokines secreted by adipose tissue, i.e. leptin and TNF-α, have been shown to vary over the menstrual cycle\textsuperscript{22–24} and influence multiple levels of the hypothalamic–pituitary–gonadal axis;\textsuperscript{18–20} prolonged hyperleptinemic states may therefore impact fertility.\textsuperscript{24} Hyperleptinaemia in excess of that driven by obesity has been shown in IIH\textsuperscript{25} and may influence fertility in IIH. These findings are unlikely to be driven by obesity alone, as we have compared with them a hospital-based PCOS population that also is typically associated with obesity.

Metabolic syndrome is associated with older age at pregnancy and infertility, independent of obesity.\textsuperscript{25} IIH is a condition characterised by metabolic dysfunction with truncal adiposity as well as insulin resistance and twice the risk of cardiovascular disease in excess of that driven by obesity.\textsuperscript{3,11}

The hyperandrogenism in IIH\textsuperscript{12} may also contribute to reproductive dysfunction, as it is hypothesised to in PCOS.\textsuperscript{1,13,26} In PCOS, reproductive function improves with dedicated treatment; further investigation for people with IIH may be beneficial.\textsuperscript{27,28} Treating metabolic perturbations with glucagon-like peptide-1 (GLP-1) receptor agonists has been shown to improve menstrual regularity and increase fertility rates in women with PCOS and obesity.\textsuperscript{29} GLP-1 receptor agonists are emerging as a potential treatment option for IIH, with preclinical data demonstrating their ability to reduce ICP and clinical efficacy data emerging.\textsuperscript{30,31}

A change in behaviour in people with a new diagnosis of IIH may contribute to the observed reduction in overall pregnancies and multiple parity. Behaviour change may be impacted by interactions with and advice from health professionals. There may be concerns that pregnancy could drive weight gain, a known risk factor for exacerbation of IIH.\textsuperscript{32,33} Targeting disease remission prior to conception is recommended and hence people with IIH may wish to delay their pregnancy until this has been achieved.\textsuperscript{33} Indeed, medicines used to lower intracranial pressure have potential teratogenic risks (acetazolamide or topiramate), which may alter family planning decisions following a diagnosis.\textsuperscript{6,33}

We observed greater pregnancy-related complications in patients with IIH. This in part may be explained by pre-pregnancy obesity and excessive weight gain in early pregnancy, which are known to increase the risk of gestational diabetes and pre-eclampsia.\textsuperscript{34} The increase in gestational diabetes and pre-eclampsia in IIH is likely to be driven by metabolic dysregulation, although the precise mechanism has yet to be established. Metabolic syndrome is an established risk factor for gestational diabetes and pre-eclampsia.\textsuperscript{35} Compared with PCOS, the gestational diabetic risk was not statistically significantly different and this likely reflects similar metabolic profiles, including a hyperandrogenic component, independent of obesity.\textsuperscript{36} Pre-eclampsia in IIH, however, warrants further investigation to establish the pathophysiological process, as this risk appears to be greater in people with IIH than in those with PCOS. The increased risk of complications in IIH are of clinical significance, as they highlight the need for increased surveillance during pregnancy.\textsuperscript{7} Pregnancy losses in IIH were comparable to the general population, unlike in PCOS, where they are increased (Table 1); this reflects previous PCOS literature with a reported OR of 1.71 (1.19–2.45).\textsuperscript{36} This should reassure IIH patients that there is no increased risk.

Maternal obesity is known to increase operative delivery rates\textsuperscript{37} and excessive gestational weight gain increases the caesarean probability by 30%.\textsuperscript{38} Elective and emergency caesarean sections were statistically significantly more likely to occur in IIH as suggested by previous literature.\textsuperscript{2} The doubling of the elective rates is of clinical significance, as these are not due to perinatal complications but are rather a planned decision prior to labour. It remains unclear whether patient and doctor concerns about normal vaginal delivery in IIH play an important role. However, raised BMI, as a cause of this increased caesarean section rate, is unlikely to be the dominant driver, given higher rates than the phenotypically similar PCOS (Figure 3B). The literature reports that caesarean section rates are noted to be higher in PCOS than in obesity-matched cohort studies (OR 1.55 [1.13–2.10])\textsuperscript{36} or PCOS with gestational diabetes (OR 1.72 [1.26–2.37]).\textsuperscript{36,39–41} This indicates that factors beyond maternal obesity are likely to contribute to operative delivery rates in these hyperandrogenic disorders. The second stage of labour only transiently elevates intracranial pressure and is unlikely to impact on optic nerve function, except in the rare case of a pregnant person with fulminant IIH. There is therefore little evidence for an elective caesarean section purely on the basis of an IIH diagnosis alone.\textsuperscript{6}

4.3 | Strengths and limitations

Idiopathic intracranial hypertension is a rare disease but the incidence is increasing. The HES data source enables large sample analysis on a national basis, which in turn assists recognition of trends potentially not identifiable from a single hospital data source. The 11 million female general population controls enable comparisons with an unaffected cohort. The additional PCOS cohort facilitates comparisons with a population predisposed to obesity with known fertility and gestational problems. We adjusted for age, as this is a known confounder for fertility and gestational complications.

There are limitations to HES data, as it is reliant on clinical record keeping and coding.\textsuperscript{43} It may be sensitive to inconsistencies,\textsuperscript{44,45} but method of delivery has been reported to be coded consistently.\textsuperscript{46} Deliveries and births are linked through HES and 98% remain linked\textsuperscript{44} with missing data
reducing over time. Previous historical data for delivery method stated 15% missing data, however, in a separate study the missing delivery method was only 0.8%. We cannot ensure that every person fulfilled the diagnostic criteria for IIH; however, the diagnosis was made in a hospital setting. IIH HES data has comparable rates of incidence and prevalence to the primary care data from evaluation of The Health Improvement Network (THIN) database.

When interrogating HES data, it is important to be cognisant that for some diseases there may be inherent bias due to a lack of clear clinical criteria that is used by clinicians for a particular diagnosis (for example, the difference between primary pre-eclampsia and superimposed pre-eclampsia). The HES dataset is hospital-based, therefore community diagnoses that do not result in hospital review or management would be underestimated, as in PCOS. This may account for diagnoses that do not result in hospital review or management would be underestimated, as in PCOS. This may account for the differences seen in PCOS fertility here (Table 1) compared with self-reported PCOS rates of infertility in the literature. This would also be the case for early miscarriages that may not need hospital or day case admissions. In addition there may be unseen coding bias, for example an emergency and semi-elective caesarean delivery does not have an international definition and has the potential to be prone to variability in coding between hospitals.

Numerical data, e.g. BMI values, are not part of this data source and so BMI could not directly be adjusted for; however, comparison was made to a PCOS population who share an obesity phenotype with IIH, therefore controlling in part for an obesity effect. Similarly those patients who do not attend hospital would not be accounted for. Infertility defined by the age-specific fertility rate is not perfect because it does not account for an individual’s relationship status or choice not to have children. Sensitive data, such as Reproductive Medicine codes for In Vitro Fertilisation, are not recorded within HES, so we are unable to establish the role of fertility treatments played in the fertility rates shown. Ectopic pregnancies were not specifically analysed in this study.

Analysing large datasets can be prone to type I statistical error. However, here we have provided descriptive outcomes rather than analysing efficacy data. The clinical context of the interpretation of the results remains important. HES offers the opportunity to find signals in rare diseases such as IIH that require further research in prospective studies to validate the findings.

5 CONCLUSION

Women with IIH had lower age-adjusted total pregnancy rates than those with PCOS and the general population. Pregnancy complication risks, including pre-eclampsia and gestational diabetes, were much higher in IIH. Following a diagnosis of IIH, elective caesarean section rates were more than doubled. A number of factors may contribute to these findings, including patient choice and systemic metabolic dysfunction. Specialist input to support reproductive health in IIH may improve outcomes.

ACKNOWLEDGEMENTS

We would like to thank the patient charity IIHUK for their wider support of our research, as well as the IIH patients who support our ongoing research.

AUTHOR CONTRIBUTIONS

MT, JM: acquisition of data; interpretation of data; drafting/revision of the manuscript for content. BRW: interpretation of data; drafting/revision of the manuscript for content. SPM: drafting/revision of the manuscript for content, including medical writing for content; and interpretation of data; AJS: study concept and design; interpretation of data; drafting/revision of the manuscript for content.

FUNDING INFORMATION

AJS is funded by a Sir Jules Thorn Award for Biomedical Science. The funding organisation had no role in the design or conduct of this research.

CONFLICT OF INTERESTS

Dr Thaller and Ms Mytton report no conflicts of interest.; Dr Wakerley reports consultancy fees (Invex therapeutics); Professor Mollan reports consultancy fees (Invex Therapeutics; Neurodiem; Velux Foundation); advisory board fees (Invex Therapeutics; Janssen; Santhera) and speaker fees (Heidelberg engineering; Chugai-Roche Ltd; Allergan; Santen; Chiesi; Santhera), all outside the submitted work. Professor Sinclair reports personal fees from Invex Therapeutics during the conduct of the study as well as share options and shareholdings; grants and funding for other trials; and speaker fees (Novartis; Allergan; Teva UK). Completed disclosure of interest forms are available to view online as supporting information.

DATA AVAILABILITY STATEMENT

Alex Sinclair takes full responsibility for the data, the analyses and interpretation, and the conduct of the research. Alex Sinclair has full access to all of the data; and has the right to publish any and all data separate. The data that support the findings of this study are available from the corresponding author upon reasonable request.

ETHICAL APPROVAL

No ethics approval was required for this study. University Hospitals Birmingham National Health Service Foundation Trust approved this study (Registered Code, Clinical Audit Registration and Management System: CARMS-17157).

ORCID

Mark Thaller https://orcid.org/0000-0001-7772-2157
Benjamin R. Wakerley https://orcid.org/0000-0003-1016-5207
Susan P. Mollan https://orcid.org/0000-0002-6314-4437
Alexandra J. Sinclair https://orcid.org/0000-0003-2777-5132

We would like to thank the patient charity IIHUK for their wider support of our research, as well as the IIH patients who support our ongoing research.

AUTHOR CONTRIBUTIONS

MT, JM: acquisition of data; interpretation of data; drafting/revision of the manuscript for content. BRW: interpretation of data; drafting/revision of the manuscript for content. SPM: drafting/revision of the manuscript for content, including medical writing for content; and interpretation of data; AJS: study concept and design; interpretation of data; drafting/revision of the manuscript for content.

FUNDING INFORMATION

AJS is funded by a Sir Jules Thorn Award for Biomedical Science. The funding organisation had no role in the design or conduct of this research.

CONFLICT OF INTERESTS

Dr Thaller and Ms Mytton report no conflicts of interest.; Dr Wakerley reports consultancy fees (Invex therapeutics); Professor Mollan reports consultancy fees (Invex Therapeutics; Neurodiem; Velux Foundation); advisory board fees (Invex Therapeutics; Janssen; Santhera) and speaker fees (Heidelberg engineering; Chugai-Roche Ltd; Allergan; Santen; Chiesi; Santhera), all outside the submitted work. Professor Sinclair reports personal fees from Invex Therapeutics during the conduct of the study as well as share options and shareholdings; grants and funding for other trials; and speaker fees (Novartis; Allergan; Teva UK). Completed disclosure of interest forms are available to view online as supporting information.

DATA AVAILABILITY STATEMENT

Alex Sinclair takes full responsibility for the data, the analyses and interpretation, and the conduct of the research. Alex Sinclair has full access to all of the data; and has the right to publish any and all data separate. The data that support the findings of this study are available from the corresponding author upon reasonable request.

ETHICAL APPROVAL

No ethics approval was required for this study. University Hospitals Birmingham National Health Service Foundation Trust approved this study (Registered Code, Clinical Audit Registration and Management System: CARMS-17157).

ORCID

Mark Thaller https://orcid.org/0000-0001-7772-2157
Benjamin R. Wakerley https://orcid.org/0000-0003-1016-5207
Susan P. Mollan https://orcid.org/0000-0002-6314-4437
Alexandra J. Sinclair https://orcid.org/0000-0003-2777-5132
REFERENCES

1. Mollan SP, Myttton J, Tsermoulas G, Sinclair AJ. Idiopathic intracranial hypertension: evaluation of admissions and emergency re-admissions through the hospital episode statistic dataset between 2002–2020. Life. 2021;11(5):417.

2. Mollan SP, Aguilar M, Evison F, Frew E, Sinclair AJ. The expanding burden of idiopathic intracranial hypertension. Eye. 2019;33(3):478–85.

3. Adderley NJ, Subramanian A, Nirantharakumar K, Yioung A, Gokhael KM, Mollan SP, et al. Association between idiopathic intracranial hypertension and risk of cardiovascular diseases in women in the United Kingdom. JAMA Neurol. 2019;76:1088–98.

4. Mollan SP, Grech O, Almajstorovic Z, Wakerley BR, Sinclair AJ. New horizons for idiopathic intracranial hypertension: advances and challenges. Br Med Bull. 2020;106(1):118–-26.

5. Mollan SP, Grech O, Sinclair AJ. Headache attributed to idiopathic intracranial hypertension and persistent post-idiopathic intracranial hypertension headache: a narrative review. Headache. 2021;61(6):808–16.

6. Mollan SP, Davies B, Silver NC, Shaw S, Mallucci CL, Wakerley BR, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018;89(10):1088–100.

7. Grech O, Clouter A, Mitchell JL, Almajstorovic Z, Ottridge RS, Yioung A, et al. Cognitive performance in idiopathic intracranial hypertension and relevance of intracranial pressure. Brain Commun. 2021;3(3):cbab202.

8. Yioung A, Mitchell JL, Nicholls M, Chong YJ, Vijay V, Wakerley BR, et al. Obstructive sleep apnoea in women with idiopathic intracranial hypertension: a sub-study of the idiopathic intracranial hypertension weight randomised controlled trial (IIH: WTT). J Neurol. 2021;1:100759.

9. Hornby C, Mollan SP, Botfield H, O’Reilly MW, Sinclair AJ. Metabolic concepts in idiopathic intracranial hypertension and their potential for therapeutic intervention. J Neuro-ophthalmol Soc. 2018;38:522–30.

10. Hornby C, Botfield H, O’Reilly MW, Westgate C, Mitchell J, Mollan SP, et al. Evaluating the fat distribution in idiopathic intracranial hypertension using dual-energy X-ray absorptiometry scanning. Neuroophthalmology. 2018;42(2):99–104.

11. Westgate CSJ, Botfield HF, Almajstorovic Z, Yioung A, Walsh M, Smith G, et al. Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension. JCI Insight. 2021;6(10):e145346.

12. O’Reilly MW, Westgate CS, Hornby C, Botfield H, Taylor AE, Markey K, et al. A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics. JCI Insight. 2019;4(6):e125348.

13. Joham AE, Tijhuis JJ, Ranasinha S, Zonggas S, Boyle J. Prevalence of infertility and use of fertility treatment in women with polycystic ovary syndrome: data from a large community-based cohort study. J Womens Health (Larchmt). 2015;24(4):299–307.

14. Mollan S, Hemnings K, Herd CP, Denton A, Williamson S, Sinclair AJ. What are the research priorities for idiopathic intracranial hypertension? A priority setting partnership between patients and health-care professionals. BMJ Open. 2019;9(3):e026573.

15. Centres of Disease Control and Prevention. International classification of diseases. 10th rev ed. Atlanta: Clinical Modification (ICD-10-CM); 2021 [cited 2021 May 26]. Available from: https://www.cdc.gov/nchs/icd/icd10cm.htm

16. NHS Digital. Office of population, censuses and surveys classification of interventions and procedures. 4th rev; 2020 [cited 2021 Oct 10]. Available from: https://isd.digital.nhs.uk/trud3/user/guest/group/0/pack/37

17. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955;19(4):251–3.

18. Gambineri A, Laudioso D, Marocco C, Radellini S, Colao A, Savastano S, et al. Female infertility: which role for obesity? Int J Obes Suppl. 2019;9(1):65–72.

19. Junghem ES, Travesio JL, Carson KR, Moley KH. Obesity and reproductive function. Obstet Gynecol Clin North Am. 2012;39(4):479–93.

20. Jain A, Polotsky AJ, Rochester D, Berga SL, Loucks T, Zeitzian G, et al. Pulsatile luteinizing hormone amplitude and progesterone metabolite excretion are reduced in obese women. J Clin Endocrinol Metab. 2007;92(7):2468–73.

21. Junghem ES, Schoeller EL, Marquard KL, Louden ED, Schaffer JE, Moley KH. Diet-induced obesity model: abnormal oocytes and persistent growth abnormalities in the offspring. Endocrinology. 2010;151(8):4039–46.

22. Brännström M, Fridén BE, Jasper M, Norman RJ. Variations in peripheral blood levels of immunoreactive tumor necrosis factor alpha (TNFalpha) throughout the menstrual cycle and secretion of TNFalpha from the human corpus luteum. Eur J Obstet Gynecol Reprod Biol. 1999;83(2):213–7.

23. Geisthovel F, Johchmann N, Widjaja A, Horn R, Brabant G. Serum pattern of circulating free leptin, bound leptin, and soluble leptin receptor in the physiological menstrual cycle. Fertil Steril. 2004;8(1):398–402.

24. Gosman GG, Katcher HI, Legro RS. Obesity and the role of gut and adipose hormones in female reproduction. Hum Reprod Update. 2006;12(5):585–601.

25. Greiger JA, Grzeskowiak LE, Smithers LG, Bianco-Miotto T, Lehmaqz SY, Andraweera P, et al. Metabolic syndrome and time to pregnancy: a retrospective study of nulliparous women. BJOG. 2019;126(7):852–62.

26. Dewally D, Andersen CT, Balen A, Broekmans F, Dilaver N, Fanchin R, et al. The physiology and clinical utility of anti-Müllerian hormone in women. Hum Reprod Update. 2014;20(3):370–85.

27. Rees DA, Jenkins-Jones S, Morgan CL. Contemporary reproductive outcomes for patients with polycystic ovary syndrome: a retrospective observational study. J Clin Endocrinol Metabol. 2016;101(4):1664–72.

28. Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2017;11(11):Cd003053.

29. Jensterle M, Janez A, Fliers E, DeVries JH, Vrtacnik-Bokal E, Siegelaar SE. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Hum Reprod Update. 2019;25(4):504–17.

30. Botfield HF, Uldall MS, Westgate CSJ, Mitchell JL, Hagen SM, Gonzalez AM, et al. A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Sci Transl Med. 2017;9(404):eaan0972.

31. Mitchell J, Walker J, Lyons H, Brock K, Vijay V, Yioung A, et al. 2 ILH pressure – a randomised, controlled, double blind physiology study of the effect of exenatide on intracranial pressure. BMJ Mill Health. 2021;167(3):el-1.

32. Ko MW, Chang SC, Ridha MA, Nye JJ, Ali TF, Friedman DI, et al. Weight gain and recurrence in idiopathic intracranial hypertension: a case-control study. Neurology. 2011;76(18):1564–7.

33. Rehrl M, Wakerley BR, Abbott S, Tahrani AA, Mollan SP, Sinclair AJ. Managing idiopathic intracranial hypertension in pregnancy: practical advice. Pract Neurol. 2022;practneuro-2021-003152. https://doi.org/10.1136/practneuro-2021-003152

34. Wendland EMDR, Duncan BB, Belizán JM, Vigo A, Schmidt MI. Gestational diabetes and pre-eclampsia: common antecedents? Arquivos Brasileiros de Endocrinologia & Metabologia. 2008;52(6):975–84.

35. Greiger JA, Bianco-Miotto T, Grzeskowiak LE, Lehmaqz SY, Poston L, McCowan LM, et al. Metabolic syndrome in pregnancy and risk for adverse pregnancy outcomes: a prospective cohort of nulliparous women. PLoS Med. 2018;15(12):e1002710.

36. Bahri Khomami M, Joham AE, Boyle JA, Piltonen T, Silagy M, Arora C, et al. Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity – a systematic review, meta-analysis, and meta-regression. Obes Rev. 2019;20(5):659–74.

37. Karmaniolou I, Petropoulos G, Theodoraki K. Management of idiopathic intracranial hypertension in parturients: anesthetic considerations. Can J Anaesth. 2011;58(7):650.
38. Goldstein RF, Abell SK, Ranasinha S, Misso M, Boyle JA, Black MH, et al. Association of Gestational Weight Gain with Maternal and Infant Outcomes: a systematic review and meta-analysis. JAMA. 2017;317(21):2207–25.
39. Alshammari A, Hanley A, Ni A, Tomlinson G, Feig DS. Does the presence of polycystic ovary syndrome increase the risk of obstetrical complications in women with gestational diabetes? J Matern Fetal Neonatal Med. 2010;23(6):545–9.
40. Foroozanfard F, Moosavi SG, Mansouri F, Bazarganipour F. Obstetric and neonatal outcome in PCOS with gestational diabetes mellitus. J Family Reprod Health. 2014;8(1):7–12.
41. Aktun HL, Yorgunlar B, Acet M, Aygun BK, Karaca N. The effects of polycystic ovary syndrome on gestational diabetes mellitus. Gynecol Endocrinol. 2016;32(2):139–42.
42. Tang RA, Dorotheo EU, Schiffman JS, Bahrani HM. Medical and surgical management of idiopathic intracranial hypertension in pregnancy. Curr Neurol Neurosci Rep. 2004;4(5):398–409.
43. Herbert A, Wijlaars L, Zylbersztejn A, Cromwell D, Hardelid P. Data resource profile: hospital episode statistics admitted patient care (HES APC). Int J Epidemiol. 2017;46(4):1093–i.
44. Harper G. Linkage of maternity hospital episode statistics data to birth registration and notification records for births in England 2005–2014: quality assurance of linkage of routine data for singleton and multiple births. BMJ Open. 2018;8(3):e017898.
45. Murray J, Saxena S, Modi N, Majeed A, Aylin P, Bottle A, et al. Quality of routine hospital birth records and the feasibility of their use for creating birth cohorts. J Public Health. 2012;35(2):298–307.
46. Knight HE, Gurov-Urganci I, Mahmood TA, Templeton A, Richmond D, van der Meulen JH, et al. Evaluating maternity care using national administrative health datasets: how are statistics affected by the quality of data on method of delivery? BMC Health Serv Res. 2013;13(1):200.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Thaller M, Mytton J, Wakerley BR, Mollan SP, Sinclair AJ. Idiopathic intracranial hypertension: Evaluation of births and fertility through the Hospital Episode Statistics dataset. BJOG. 2022;00:1–9. https://doi.org/10.1111/1471-0528.17241